biostudies-literatureUnknown11(15)Zhao YThe lack of tumor specific antigens (TSA) and the immune tolerance are two major obstacles for the immunotherapy of cancer. Current immune checkpoint inhibitors (ICIs) show clinical responses in only limited subsets of cancer patients, which, to some extent, depends on the mutation load of tumor cells that may generate neoantigens. Here, we aimed to generate a neoantigen MDP to exhibit stronger anti-tumor efficacy. <b>Methods:</b> In this study, we utilized chemically modified sialic acid precursor tetra acetyl-N-azidoacetyl-mannosamine (AC₄ManNA_Z) to engineer the glycoproteins on the membranes of tumor cells for the covalent ligation of hapten adjuvant Pam3CSK4 <i>in vivo</i>, which eventually generated a neoantigen, i.e., ManNA_Z-DBCO-Pam3CSK4 (MDP), on tuTheranostics7425-7438https://www.ebi.ac.uk/biostudies/studies/S-EPMC8210591biostudies-literatureGeneration of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.PMC8210591Lv JXiang RLiu YLi JLi SQin XChen YChen XWang XShi JZhao YShi YfalseGeneration of triacyl lipopeptide-modified glycoproteins by metabolic glycoengineering as the neoantigen to boost anti-tumor immune response.The lack of tumor specific antigens (TSA) and the immune tolerance are two major obstacles for the immunotherapy of cancer. Current immune checkpoint inhibitors (ICIs) show clinical responses in only limited subsets of cancer patients, which, to some extent, depends on the mutation load of tumor cells that may generate neoantigens. Here, we aimed to generate a neoantigen MDP to exhibit stronger anti-tumor efficacy. <b>Methods:</b> In this study, we utilized chemically modified sialic acid precursor tetra acetyl-N-azidoacetyl-mannosamine (AC₄ManNA_Z) to engineer the glycoproteins on the membranes of tumor cells for the covalent ligation of hapten adjuvant Pam3CSK4 <i>in vivo</i>, which eventually generated a neoantigen, i.e., ManNA_Z-DBCO-Pam3CSK4 (MDP), on tu2021-01-01T00:00:00Z20212025-04-04T09:30:35.328Z2022-02-10T16:01:23.969ZS-EPMC82105913415885810.7150/thno.60211